Efficacy and safety of anidulafungin in elderly, critically ill patients with invasive Candida infections: a post hoc analysis (Articolo in rivista)

Type
Label
  • Efficacy and safety of anidulafungin in elderly, critically ill patients with invasive Candida infections: a post hoc analysis (Articolo in rivista) (literal)
Anno
  • 2012-01-01T00:00:00+01:00 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#doi
  • 10.1016/j.ijantimicag.2012.07.018 (literal)
Alternative label
  • Dimopoulos, G.; Paiva, J.A.; Meersseman, W.; Pachl, J.; Grigoras, I.; Sganga, G.; Montravers, P.; Auzinger, G.; Borges Sa, M.; Miller, P.J.; Marcek, T.; Kantecki, M.; Ruhnke, M. (2012)
    Efficacy and safety of anidulafungin in elderly, critically ill patients with invasive Candida infections: a post hoc analysis
    in International journal of antimicrobial agents (Print); ELSEVIER SCIENCE BV, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS, AMSTERDAM (Paesi Bassi)
    (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori
  • Dimopoulos, G.; Paiva, J.A.; Meersseman, W.; Pachl, J.; Grigoras, I.; Sganga, G.; Montravers, P.; Auzinger, G.; Borges Sa, M.; Miller, P.J.; Marcek, T.; Kantecki, M.; Ruhnke, M. (literal)
Pagina inizio
  • 521 (literal)
Pagina fine
  • 526 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume
  • 40 (literal)
Rivista
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroFascicolo
  • 6 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni
  • Dimopoulos, G.. Univ Athens, Dept Crit Care, Univ Hosp ATTIKON, Sch Med, Athens, Greece Paiva, J.A.: Hosp Sao Joao, Oporto, Portugal Meersseman, W.: Katholieke Univ Leuven Hosp, Louvain, Belgium Pachl, J.: Univ Hosp Kralovske Vinohrady, Prague, Czech Republic Grigoras, I.: Univ Med & Pharm, Iasi, Romania Sganga, G.: Catholic Univ, Hosp Agostino Gemelli, Rome, Italy Montravers, P.: Hop Bichat Claude Bernard, F-75877 Paris 18, France Auzinger, G.: Kings Coll Hosp, London, England Borges Sa, M.: Hosp Son Llatzer, Palma De Mallorca, Spain Miller, P.J.: Pfizer Global Res & Dev, Sandwich, Kent, England Marcek, T.; Kantecki, M.: Pfizer Int Operat, Specialty Care, Paris, France Ruhnke, M.: Charite, Berlin, Germany (literal)
Titolo
  • Efficacy and safety of anidulafungin in elderly, critically ill patients with invasive Candida infections: a post hoc analysis (literal)
Abstract
  • Post hoc analysis of a non-comparative, prospective, multicentre, phase IIIb study was performed to compare efficacy and safety of anidulafungin in elderly (>= 65 years) versus non-elderly (<65 years) Intensive Care Unit (ICU) patients with candidaemia/invasive candidiasis (C/IC). Adult ICU patients with confirmed C/IC meeting >= 1 of the following criteria were enrolled: post-abdominal surgery; solid tumour; renal/hepatic insufficiency; solid organ transplantation; neutropenia; age >= 65 years. Patients received anidulafungin (200 mg on Day 1, 100 mg/day thereafter) for >= 10 days followed by optional azole step-down therapy for a total treatment duration of 14-56 days. The primary efficacy endpoint was global (clinical and microbiological) response at the end of all therapy (EOT). Primary efficacy analysis was performed in the modified intent-to-treat (mITT) population (n = 170), excluding unknown and missing responses. In total, 80 patients (47.1%) were aged >= 65 years and 90 (52.9%) were aged <65 years; the mean age difference between the two groups was 21.9 years. Global success at EOT in mITT patients was similar in elderly (68.1%) and non-elderly (70.7%) patients (P = 0.719). However, global success rates were significantly lower in elderly versus non-elderly patients at 2 and 6 weeks after EOT (P = 0.045 and P = 0.016, respectively). Ninety-day survival was significantly lower (P = 0.006) for elderly (42.8%) versus non-elderly patients (63.3%). The incidence and profile of adverse events were similar in elderly and non-elderly patients. Anidulafungin was effective and safe for treatment of C/IC in elderly ICU patients, despite higher baseline severity of illness scores. (c) 2012 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved (literal)
Editore
Prodotto di
Autore CNR

Incoming links:


Prodotto
Autore CNR di
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#rivistaDi
Editore di
data.CNR.it